4//SEC Filing
Morlock Stephen 4
Accession 0001424422-17-000011
CIK 0001504167other
Filed
Nov 26, 7:00 PM ET
Accepted
Nov 27, 5:06 PM ET
Size
10.4 KB
Accession
0001424422-17-000011
Insider Transaction Report
Form 4
BioPharmX Corpbpmx
Morlock Stephen
Director
Transactions
- Purchase
Warrant to purchase common stock
2017-11-24+330,000→ 330,000 totalExercise: $0.25→ Common stock (330,000 underlying) - Purchase
Common stock
2017-11-24$0.15/sh+330,000$49,500→ 873,956 total - Purchase
Warrant to purchase common stock
2017-11-24+330,000→ 330,000 totalExercise: $0.20→ Common stock (330,000 underlying)
Holdings
- 251,071(indirect: By Stephen W. Morlock and Karen R. Morlock TTE UDT dated 04/21/03)
Common stock
Footnotes (4)
- [F1]Securities are purchased as a unit, priced at $0.15 per unit, which consists of one share of common stock, one Series A warrant to purchase one share of common stock and one Series B warrant to purchase one share of common stock.
- [F2]Mr. Morlock is a co-trustee and co-beneficiary of the Stephen W. Morlock and Karen R. Morlock TTE UDT dated 04/21/03
- [F3]This Series A warrant is immediately exercisable and expires on 11/24/2022.
- [F4]This Series B warrant is immediately exercisable and expires on the earlier of (1) the 21st trading day after the Company issues a press release announcing it has entered into a strategic licensing, collaboration, partnership or similar agreement for the commitment to fund its phase 3 trials for BPX01 and (2) the 18 month anniversary of issuance.
Documents
Issuer
BioPharmX Corp
CIK 0001504167
Entity typeother
Related Parties
1- filerCIK 0001637670
Filing Metadata
- Form type
- 4
- Filed
- Nov 26, 7:00 PM ET
- Accepted
- Nov 27, 5:06 PM ET
- Size
- 10.4 KB